Research is underway to determine the health benefits of Cannabigerol or CBG. First, this article will explore its potential to treat inflammatory diseases, glaucoma, and neuroprotective properties.
In addition to CBD, the cannabis plant contains 111 other cannabinoids. But, cannabinoids have received the most attention. Among them is cannabigerol, a tri-lettered cannabinoid, also known as CBG. Read on and explore what is CBG good for. While CBG is not as widely known as its CBD and THC counterparts, it has the potential to become the world’s most sought-after cannabis-derived concentrate.
This cannabinoid is more prevalent in young cannabis plants, but there are some notable differences between cannabigerol and CBD. The former contains more of the active ingredient in marijuana, while the latter is derived from the plant’s mature form. Cannabigerol is not psychoactive and is non-addictive. It can even help prevent Huntington’s disease. It also has promising potential to help treat various ailments, including intraocular pressure and motor deficits.
Researchers have found that cannabigerol has potential therapeutic benefits in treating Huntington’s disease. It was synthesized in 1996 and is promising as an inhibitor of nerve degeneration. In addition, it has been shown to protect the brain from damage and improve cognitive function in patients with Huntington’s disease.
Cannabigerol, also known as cannabigerol acid, is produced from two compounds in the cannabis plant. The two compounds interact with plant enzymes to produce cannabinoids. These substances may have neuroprotective properties and be the next big thing. Using cannabigerol could help treat glaucoma. It can slow the growth of cancerous cells and improve vision.
Cannabigerol’s Potential in Treating Glaucoma
Cannabigerol is one of the minor cannabinoids found in marijuana, and researchers are exploring its potential in treating glaucoma. The drug decreases intraocular pressure and may be particularly effective in lowering pressure and accelerating fluid drainage. Although the drug’s potential for treating glaucoma remains unproven, the study’s findings are promising.
Though the American Academy of Ophthalmology does not endorse marijuana for glaucoma treatment, mounting scientific evidence points to a possible role for cannabinoids in reducing IOP. One of the most recent studies, by InMed Pharmaceuticals in collaboration with the University of British Columbia, showed promising results in animal models of glaucoma. In addition, although cannabinoids have traditionally been helpful for glaucoma treatment, newer studies indicate that CBG may have a much better effect.
Cannabigerol’s Potential in Treating Inflammatory Diseases
Recent studies have revealed promising anti-inflammatory and therapeutic benefits of CBG. One study looked at its effects on skin conditions. Another study discovered that CBG lowered nitric oxide production and blocked the development of ROS in intestinal epithelial cells. These findings imply that CBG might be utilized to treat inflammatory disorders. However, further research is needed to determine CBG’s potential for treating inflammatory disorders.
While clinical trials have revealed promise in animal models, CBG’s effectiveness in humans is not yet apparent. Research has only been conducted in laboratory animals and tissues; further human studies are needed to confirm these results. Regardless of whether CBG is a viable treatment for any inflammatory diseases, it has tremendous potential as a novel pharmacological agent for treating neurodegenerative diseases. Inflammatory bowel disease, Crohn’s disease, and cancer may be among the conditions that benefit from CBG. Inflammatory bowel disease, CBG, has also been shown to be an effective treatment for Crohn’s disease. It also improves the symptoms of glaucoma and abnormally high intraocular pressure, two inflammatory disorders.
Cannabigerol’s potential in treating fat storage
Recent studies have shown that cannabigerol has therapeutic properties against obesity and other related diseases and has anti-inflammatory and analgesic effects. Moreover, cannabigerol quinone derivative VCE-003.2 has low adipogenic activity but showed neuroprotective and antiinflammatory effects against HD models in vivo. Furthermore, it is the only cannabinoid with such activity.